REGION – NAME: REGIONE LAZIO - ACT Operations Research IT srl


TITLE Platform for early and non-invasive diagnostics of neurodegenerative diseases


The project aims to improve the diagnostic accuracy of neurodegenerative diseases by integrating Artificial Intelligence and with Innovative Biomarkers.
Low sensitivity and specificity of current diagnostic methodologies lead to frequent dementia misdiagnosis; this raises the need of more efficient integration of biomarkers with multidimensional clinical data. Our goal, through an interdisciplinary approach, is to implement a new diagnostic mathematical model by mining large databases of clinical variables of Mild Cognitive Impairment, Alzheimer's disease and other demented patients and controls subjects for providing probabilistic early diagnoses. The activities include the development of a detailed Ontology for multidimensional clinical datasets, the implementation of Artificial Intelligence methods to extract knowledge, the measurement of innovative biomarkers in clinical biological samples.

The diagnostic models will allow focusing on essential clinical variables and support clinicians in the early diagnostic process.
The project, of value around 1 million euros, is developed by ACT Operations Research, a math-technology company, European Brain Research Institute founded by the Nobel Prize winner Rita Levi-Montalcini, and the Italian National Research Council.
We are interested in finding research, industrial and financial partners to set up a Bio-Informatics & Modelling (BI&M) competence center, to support the healthcare sector with Artificial Intelligence and Advanced Modelling techniques.


To evaluate the business opportunity proposed with the project has to be considered: the background, the market position, and the scaling plan of ACT Operations Research (ACT OR).


ACT OR is a math-technology company. ACT OR, based on a proprietary decision science platform, supports crucial business decisions and process control by advanced analytics as math-optimization, artificial intelligence, dynamic simulators, and predictive models. Such software technologies, combined with “big data” supports complex decisions and systems control.
The ACT OR decision-science platform enables sophisticated “what-if” analysis as well as the real-time optimization (example are supply chain optimization, dynamic price optimization, simulators etc.). The application of such technology and expertise in the fields of robotics and science of life is a strategic line of development for ACT OR. After intensive work, developing know-how, references, and technology, ACT OR is now acting to grow internationally.
Highly contribute to the co-development of innovative solutions for the diagnosis and care the joint-ventures with excellence centers like the European Brain Research Institute (EBRI) “Rita Levi-Montalcini Institute (Roma, Italy) and the Italian National Research Council (IASI-CNR; Roma, Italy), with the know-how of Innovative Biomarkers in the Neurodegenerative diseases and data mining and new algorithms.


The acronym of the project is MoDiag, which stands for Modelling for Diagnostics.
The idea behind such a research project is the development of services and technology in the science of life and healthcare areas.
The ideas come from the awareness that advanced modelling techniques could dramatically and positively impact the prevention, early diagnostics, and care of diseases. In addition, the decision science improves the operations, the service level, and reduce costs of hospitals, clinics, and laboratories.
Is not easy for a hospital, a medical organization, a bio-science laboratory, where the prevalent culture comes from other disciplines, to adopt such techniques and technologies.
The ACT OR projects aims to offer services in the mentioned fields, by a Bio-Informatics & Modelling (BI&M) competence center, levering the existing ACT OR expertise and technologies combined with medical and bio-science competences of European Brain Research Institute (EBRI) “Rita Levi-Montalcini Institute (Roma, Italy) and the Italian National Research Council (IASI-CNR; Roma, Italy).

At the base of the mentioned technology, there is a multi-analytical decision science platform (called Bloomy Decision), permitting the fast-built & deploy of web-based analytical applications. Parallel & distributed computing, the capability to manage a big amount of data efficiently are a crucial characteristic of such a platform.
The solution, by the decision science platform, enable the application of artificial intelligence for the early diagnosis of diseases. The platform is specialized for the type of disease starting from the most impacting such as the Alzheimer’s disease. The platform can be used by a single center or clusters of centers under a cooperation agreement. The platform can also be used for research activities. The MoDiag project is financing the set-up of such a solution.

ECONOMICS (preliminary):

In the world >50M people suffer from dementia, with a rough global cost exceeding 500 billion Euro.
In Italy it is estimated that >1,000,000 people suffer from dementia, of which >600,000 are affected by Alzheimer’s Disease, and family members involved in caregiving are estimated to be > 3,000,000. The average cost per patient is 9,000-16,000/year, with a total cost > 12 billion Euro. This is potentially a very large market, including 478 Dementia centres (34 in Roma Region) in public health services only, to which a large increasing private market must be added.
The economic advantage for an early and accurate diagnosis would lead to a substantial cost saving, particularly for home caregivers and hospitalisation. Furthermore this would allow to start as soon as possible a proper drug therapy, that would slow down or delay the disease onset. Delaying the AD onset would lead to a net decrease of patients number, with a consequent cost saving for health system. US Alzheimer’s Association estimates that, if in 2025 a new drug able to delay AD onset by 5 years would come to market, people affected by AD would decrease by 40% by 2050, with a related direct and indirect costs saving up to 36% (Biopharmaceutical Research Companies, 2013 Report; Alzheimer's Association: Changing the trajectory of AD disease, 2015).

A similar model in the UK, where almost 1 million people are affected by dementia, shows that if a new disease modifying drug would be made available on the market in 2020, this would lead to a decrease in patients and cost of about 20%, with a disease onset delayed of 2 years and about 35% if the drug is able to delay by 5 years the onset. The cost saving would be equally distributed between direct costs and indirect costs (from Alzheimer's Research UK, Defeat Dementia, 2015).
Concerning misdiagnosis, a US study estimates that the excess medical cost for Parkison’s Disease misdiagnosis, often with symptoms overlapping other forms of dementia, may exceed 10000 Euro/year of incorrect diagnosis. This underlines that not only an early, but also reliable and diagnosis, are crucial for saving healthcare costs.
Delaying the disease onset not only would substantially decrease the economic burden for public health systems and families, but would also immensely benefit patients and their relatives from the social and psychological point of view, with a positive impact on the quality of everyday life.
With the MoDiag project we aim to offer client-server based services to public and private neurology and geriatric departments, on a cost/year basis, which will provide in-silico diagnostics and diagnostic work-flow optimization. Moreover, as the patient database will increase in size thanks to new data entry by the health personnel, the system will also select new biomarkers and clinical endpoints with increasing statistical reliability.

Our Healthcare Operations Planning aims to develop, considering the ROI such solution, an application to predict, simulate and plan resources for early and most accurate diagnosis with a cost from 5K€ to 80K€/ year. Set-up services to be added for about 20-80 K€ per application.
A solution for the optimization of the drugs inventory can cost from 2 to 20 K€ per year per warehouse and a set-up fee around 10-80 K€.
Diagnostics Intelligence: 30-80 €/patience per year per type of disease.

New investments may be crucial for:

  • server system management,
  • development of more efficient modelling and data mining approaches
  • client side customization to deal with the high heterogeneity of the Italian Health system
  • Marketing of services
  • New Biomarkers validation in clinical trials
  • Financial evaluation and modeling of cost saving impact on Health institutions


Characterized by continuous research, ACT OR is also a shareholder of a spinoff of Sapienza University in Rome, Italy, focused on Operations Research themes. The ACT OR team is composed of 40 specialists which include several PhDs.
ACT OR has over 20 years of experience in operations research, predictive analytics, artificial intelligence, simulators, and advanced control logic.
After intensive work, developing know-how, references, and technology, ACT OR is now acting to grow internationally.
The ACT OR's activities include the participation to several Research & Development projects financed by European funds.
As a testimony of the ACT OR expertise, we noted that, by a project for the customer Europcar (HQ Paris - FR) have been selected as finalists by the Institute for Operations Research and Management Science (INFORMS) for Franz Edelman Award, the world’s most prestigious international award for achievement in the practice of Operations Research.
ACT OR, presenting the characteristics of a start-up, from the innovation perspective, is a low-risk and high potential opportunity for investors willing to lever the emerging market of the Advanced analytics, Artificial intelligence
ACTOR has offices in Italy with Rome and Milan and is now working on an international expansion. We’ve established ACTOR UK (London) and ACTOR US (Charlotte, NC).


e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it. ; This email address is being protected from spambots. You need JavaScript enabled to view it.
telefono: 335.499619

Contact person:
Raffaele Maccioni / Giuseppe Confessore